The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancer

Detalhes bibliográficos
Autor(a) principal: Guimarães, Júlia Silva Jayme
Data de Publicação: 2024
Outros Autores: Gomes, Maria Clara Tassara, Moura, Bianca Dubberstein, Silva, Patrícia Naves, Gomes, João Paulo Teixeira, Vian, Marcela Andrade, Leão, Marina Cabral, Soave, Danilo Figueiredo
Tipo de documento: Artigo
Idioma: por
Título da fonte: Brazilian Journal of Health Review
Texto Completo: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/67502
Resumo: Introduction: Gastric cancer is a chronic non-communicable disease that is increasingly recurring around the world. Based on this theme, we know the importance of adequate treatment to avoid negative repercussions on health. Therefore, it is necessary to identify the PPIs most used as an adjunct in the treatment of potential gastric lesions for the development of neoplasia. Material and methods: This is an integrative review of the literature on the therapeutic use of proton pump inhibitors associated with the development of gastric cancer. To problematize the research, the following guiding question was used: What are the PPIs most used as an adjunct in the treatment of gastric lesions that are potential for the development of gastric cancer? The database provided by (PUBMED) was used for research. To correctly search for terms, the key words were checked in DeCS. Results: The main antibiotics identified were: amoxicillin, clarithromycin and tetracillin, and the main PPIs: Omeprazole, vanoprazole, rabeprazole, metronidazole and lansoprazole. The antibiotic, amoxicillin, and the PPIs omeprazole, were the most common medications in the study. However, with different associations. The duration of use of the drug combinations ranged from 10 days to 4 weeks, however, most articles showed a relationship with the eradication of the bacteria after using the drug combination. Conclusion: The antibiotic, amoxicillin, and the PPIs, omeprazole, were the most common medications in the study. However, with different combinations. Therefore, it can be concluded that there is no standardized treatment to reduce potential lesions for the development of gastric neoplasms. Therefore, it is worth highlighting the importance of more studies that can address this issue that has a major impact on public health.
id BJRH-0_e337a63f7e0095f93c16ca419a7ca233
oai_identifier_str oai:ojs2.ojs.brazilianjournals.com.br:article/67502
network_acronym_str BJRH-0
network_name_str Brazilian Journal of Health Review
repository_id_str
spelling The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancerdrug therapystomach neoplasmsproton pump inhibitorsIntroduction: Gastric cancer is a chronic non-communicable disease that is increasingly recurring around the world. Based on this theme, we know the importance of adequate treatment to avoid negative repercussions on health. Therefore, it is necessary to identify the PPIs most used as an adjunct in the treatment of potential gastric lesions for the development of neoplasia. Material and methods: This is an integrative review of the literature on the therapeutic use of proton pump inhibitors associated with the development of gastric cancer. To problematize the research, the following guiding question was used: What are the PPIs most used as an adjunct in the treatment of gastric lesions that are potential for the development of gastric cancer? The database provided by (PUBMED) was used for research. To correctly search for terms, the key words were checked in DeCS. Results: The main antibiotics identified were: amoxicillin, clarithromycin and tetracillin, and the main PPIs: Omeprazole, vanoprazole, rabeprazole, metronidazole and lansoprazole. The antibiotic, amoxicillin, and the PPIs omeprazole, were the most common medications in the study. However, with different associations. The duration of use of the drug combinations ranged from 10 days to 4 weeks, however, most articles showed a relationship with the eradication of the bacteria after using the drug combination. Conclusion: The antibiotic, amoxicillin, and the PPIs, omeprazole, were the most common medications in the study. However, with different combinations. Therefore, it can be concluded that there is no standardized treatment to reduce potential lesions for the development of gastric neoplasms. Therefore, it is worth highlighting the importance of more studies that can address this issue that has a major impact on public health.Brazilian Journals Publicações de Periódicos e Editora Ltda.2024-02-23info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/6750210.34119/bjhrv7n1-556Brazilian Journal of Health Review; Vol. 7 No. 1 (2024); 6833-6844Brazilian Journal of Health Review; Vol. 7 Núm. 1 (2024); 6833-6844Brazilian Journal of Health Review; v. 7 n. 1 (2024); 6833-68442595-6825reponame:Brazilian Journal of Health Reviewinstname:Federação das Indústrias do Estado do Paraná (FIEP)instacron:BJRHporhttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/67502/48063Guimarães, Júlia Silva JaymeGomes, Maria Clara TassaraMoura, Bianca DubbersteinSilva, Patrícia NavesGomes, João Paulo TeixeiraVian, Marcela AndradeLeão, Marina CabralSoave, Danilo Figueiredoinfo:eu-repo/semantics/openAccess2024-02-27T14:30:14Zoai:ojs2.ojs.brazilianjournals.com.br:article/67502Revistahttp://www.brazilianjournals.com/index.php/BJHR/indexPRIhttps://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/oai|| brazilianjhr@gmail.com2595-68252595-6825opendoar:2024-02-27T14:30:14Brazilian Journal of Health Review - Federação das Indústrias do Estado do Paraná (FIEP)false
dc.title.none.fl_str_mv The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancer
title The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancer
spellingShingle The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancer
Guimarães, Júlia Silva Jayme
drug therapy
stomach neoplasms
proton pump inhibitors
title_short The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancer
title_full The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancer
title_fullStr The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancer
title_full_unstemmed The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancer
title_sort The combined use of proton pump inhibitors with the most commonly used antibiotics in drug therapy for gastric cancer
author Guimarães, Júlia Silva Jayme
author_facet Guimarães, Júlia Silva Jayme
Gomes, Maria Clara Tassara
Moura, Bianca Dubberstein
Silva, Patrícia Naves
Gomes, João Paulo Teixeira
Vian, Marcela Andrade
Leão, Marina Cabral
Soave, Danilo Figueiredo
author_role author
author2 Gomes, Maria Clara Tassara
Moura, Bianca Dubberstein
Silva, Patrícia Naves
Gomes, João Paulo Teixeira
Vian, Marcela Andrade
Leão, Marina Cabral
Soave, Danilo Figueiredo
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Guimarães, Júlia Silva Jayme
Gomes, Maria Clara Tassara
Moura, Bianca Dubberstein
Silva, Patrícia Naves
Gomes, João Paulo Teixeira
Vian, Marcela Andrade
Leão, Marina Cabral
Soave, Danilo Figueiredo
dc.subject.por.fl_str_mv drug therapy
stomach neoplasms
proton pump inhibitors
topic drug therapy
stomach neoplasms
proton pump inhibitors
description Introduction: Gastric cancer is a chronic non-communicable disease that is increasingly recurring around the world. Based on this theme, we know the importance of adequate treatment to avoid negative repercussions on health. Therefore, it is necessary to identify the PPIs most used as an adjunct in the treatment of potential gastric lesions for the development of neoplasia. Material and methods: This is an integrative review of the literature on the therapeutic use of proton pump inhibitors associated with the development of gastric cancer. To problematize the research, the following guiding question was used: What are the PPIs most used as an adjunct in the treatment of gastric lesions that are potential for the development of gastric cancer? The database provided by (PUBMED) was used for research. To correctly search for terms, the key words were checked in DeCS. Results: The main antibiotics identified were: amoxicillin, clarithromycin and tetracillin, and the main PPIs: Omeprazole, vanoprazole, rabeprazole, metronidazole and lansoprazole. The antibiotic, amoxicillin, and the PPIs omeprazole, were the most common medications in the study. However, with different associations. The duration of use of the drug combinations ranged from 10 days to 4 weeks, however, most articles showed a relationship with the eradication of the bacteria after using the drug combination. Conclusion: The antibiotic, amoxicillin, and the PPIs, omeprazole, were the most common medications in the study. However, with different combinations. Therefore, it can be concluded that there is no standardized treatment to reduce potential lesions for the development of gastric neoplasms. Therefore, it is worth highlighting the importance of more studies that can address this issue that has a major impact on public health.
publishDate 2024
dc.date.none.fl_str_mv 2024-02-23
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/67502
10.34119/bjhrv7n1-556
url https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/67502
identifier_str_mv 10.34119/bjhrv7n1-556
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/67502/48063
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Brazilian Journals Publicações de Periódicos e Editora Ltda.
publisher.none.fl_str_mv Brazilian Journals Publicações de Periódicos e Editora Ltda.
dc.source.none.fl_str_mv Brazilian Journal of Health Review; Vol. 7 No. 1 (2024); 6833-6844
Brazilian Journal of Health Review; Vol. 7 Núm. 1 (2024); 6833-6844
Brazilian Journal of Health Review; v. 7 n. 1 (2024); 6833-6844
2595-6825
reponame:Brazilian Journal of Health Review
instname:Federação das Indústrias do Estado do Paraná (FIEP)
instacron:BJRH
instname_str Federação das Indústrias do Estado do Paraná (FIEP)
instacron_str BJRH
institution BJRH
reponame_str Brazilian Journal of Health Review
collection Brazilian Journal of Health Review
repository.name.fl_str_mv Brazilian Journal of Health Review - Federação das Indústrias do Estado do Paraná (FIEP)
repository.mail.fl_str_mv || brazilianjhr@gmail.com
_version_ 1797240043058757632